Researchers evaluated the response rate of gemcitabine in patients with platinum-resistant ovarian cancer given at a low dosage. Their research was presented at the Hematology/Oncology Pharmacy...
The US Food and Drug Administration granted regular approval to a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
